Advertisement

Topics

Symbiotix Biotherapies, Inc. Company Profile

15:45 EDT 20th June 2019 | BioPortfolio

Symbiotix Biotherapies, Inc. is a pioneering microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College. Symbiotix is developing a novel class of Treg-modulating therapeutics based on molecules derived from the human microbiome. As one of the earliest companies in the microbiome sector, our most advanced clinical candidate has been described in over 100 scientific publications, represents the most well studied microbiome-derived molecule to date, and is now protected by issued composition-of-matter patents. Symbiotix is dedicated to delivering first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. For more information, please visit www.symbiotix-bio.com.


News Articles [16 Associated News Articles listed on BioPortfolio]

Be The Match BioTherapies Announces Strategic Collaboration with Kiadis Pharma to Accelerate Patient Access to Haploidentical Stem Cell Therapies

Collaboration will support Phase III clinical trial of cell therapy product ATIR101 for blood cancers Be The Match BioTherapies, an organization offering solutions for companies developing and com...

Gamida Cell and Be The Match BioTherapies Announce Strategic Collaboration

Gamida Cell (Nasdaq:GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies, a subsidiary of the National Marrow Donor Program®/Be The Match® offering integrated ...

Be The Match BioTherapies® Announces Collaboration with National Health Service Blood and ...

Collaboration aims to streamline access to authorized collection and processing centers Read more...

Poseida Therapeutics, Be The Match BioTherapies team up on CAR-T logistics

The two companies will collaborate to ensure timely

Collaboration will focus on providing cancer CAR T-cell therapies

Poseida Therapeutics and Be The Match BioTherapies have partnered to deliver autologous chimeric antigen receptor T-cell ther -More- 

Be The Match BioTherapies® Announces Collaboration with Poseida Therapeutics to Support Development of Life-Saving Cellular Therapies

Be The Match BioTherapies will provide end-to-end support services to accelerate clinical development of Poseida’s autologous BCMA and PSMA CAR-T programs B...

Be The Match BioTherapies® and TrakCel Partner to Standardize Cell and Gene Therapy Supply Chain Solutions

Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and

Be The Match BioTherapies® Announces Collaboration with National Health Service Blood and Transplant of the United Kingdom

Collaboration aims to streamline access to authorized collection and processing centers Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing ...

Drugs and Medications [0 Results]

None

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Biotherapies: a revolution on the move.

Changes in persistent asthma care and outcomes from 2006 to 2016 in France.

Changes in asthma care need to be documented at arrival of biotherapies.

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis.

Three biotherapies - etanercept, adalimumab, and ustekinumab - are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. Howe...

New treatments in respiratory medicine in 2018 : asthma, cystic fibrosis and nocturnal positive pressure (CPAP or NIV).

In this review of novel therapies in pulmonary disorders in 2018, we cover 3 different entities. In GINA stage 1 and 2 asthma, new strategies allow a more individualized treatment. In more severe asth...

Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss).

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome, is a systemic necrotizing vasculitis of small- and medium-size vessels, characterized by asthma and blood ...

Clinical Trials [14 Associated Clinical Trials listed on BioPortfolio]

Biotherapies and Therapeutic Education in Chronic Inflammatory Rheumatism

The hypothesis is that group interaction associated with individual interviews intensify the acquisition of safety skills compared to individual interviews alone in patients with CIR treat...

COLISURG Prospective, Multicentric Cohort

The surgical treatment of the ulcerative colitis (UC) remains associate to a significant morbidity (up to 60%). Anastomotic fistula and pelvic sepsis are the most severe complications whic...

Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis

PSOBIOTEQ is a national multicentric prospective cohort of cutaneous psoriasis patients receiving systemic treatment (biotherapy or DMARDs) for moderate to severe cutaneous psoriasis. It i...

Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers

The aim of this trial is the caracterisation of a predicting algorithm of the answering response for patients with etanercept treatment in spondyloarthritis disease. This algorithm will h...

Impact of Behavioral Factors on Treatment Adherence in a Sample of Rheumatoid Arthritis Patients

Rheumatoid arthritis (RA) care has been revolutionized in the last decade with the advent of biotherapies. Only 66% of treated patients are compliant. Nevertheless, studies analyzing the m...

Companies [5 Associated Companies listed on BioPortfolio]

Symbiotix Biotherapies, Inc.

Symbiotix Biotherapies, Inc. is a pioneering microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital/Harvard Medical School, Cal...

Biotherapies Incorporated

Biotherapies, Inc developing a new therapy and diagnostics for breast cancer. Access to company information, technology and research updates provided.

Be The Match BioTherapies

Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development—from discovery through commercialization. Built...

CSL Biotherapies

CSL Biotherapies has an initial contract worth $180 million to deliver bulk H1N1 vaccine antigen to the U.S. Health and Human Services Department (HHS), with an option for filling...

Be The Match BioTherapies®

More Information about "Symbiotix Biotherapies, Inc." on BioPortfolio

We have published hundreds of Symbiotix Biotherapies, Inc. news stories on BioPortfolio along with dozens of Symbiotix Biotherapies, Inc. Clinical Trials and PubMed Articles about Symbiotix Biotherapies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Symbiotix Biotherapies, Inc. Companies in our database. You can also find out about relevant Symbiotix Biotherapies, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record